Document Detail

One-Year Efficacy and Safety Study of a 1.62% Testosterone Gel in Hypogonadal Men: Results of a 182-Day Open-Label Extension of a 6-Month Double-Blind Study.
MedLine Citation:
PMID:  22321357     Owner:  NLM     Status:  Publisher    
Introduction.  A new formulation of testosterone gel (1.62% testosterone gel) with increased viscosity and reduced volume of application has been shown to be safe and efficacious after 182 days of use in a phase 3, double-blind study in adult hypogonadal males. Aim.  The objective of this study was to evaluate the efficacy and safety of the 1.62% testosterone gel after daily application to the skin in a 182-day (6-month) open-label extension of the initial 182-day double-blind study. Methods.  One hundred and sixty-three subjects, aged 26 to 77 years, continued on active (Continuing Active subjects) 1.62% testosterone gel for the remainder of the study (364 days total). In 28 subjects who had previously received placebo (Formerly Placebo subjects), the dose was titrated to normal levels of serum total testosterone (300-1,000 ng/dL). Dose adjustments for both groups were allowed at specific visits to maintain serum testosterone within a normal range. Main Outcome Measure.  The main outcome measure was the percentage of subjects with serum total testosterone average concentrations (C(av) ) within the normal range at day 364. Results.  On day 364, 77.9% (95% confidence interval: 70.0, 84.6) of the Continuing Active subjects and 87.0% (66.4, 97.2) of the Formerly Placebo subjects had C(av) values within the eugonadal range. The 1.62% testosterone gel was safe and well tolerated in this study. Conclusion.  Treatment with 1.62% testosterone gel for up to 1 year (182 days for the Formerly Placebo subjects, 364 days for the Continuing Active subjects) was safe and efficacious, resulting in >77% of treated subjects achieving normal serum testosterone levels at final visit. Kaufman JM, Miller MG, Fitzpatrick S, McWhirter C, and Brennan JJ. One-year efficacy and safety study of a 1.62% testosterone gel in hypogonadal men: Results of a 182-day open-label extension of a 6-month double-blind study. J Sex Med **;**:**-**.
Joel M Kaufman; Michael G Miller; Sherahe Fitzpatrick; Cecilia McWhirter; John J Brennan
Related Documents :
16287097 - Circulating em66 is a highly sensitive marker for the diagnosis and follow-up of pheoch...
6233357 - Adrenal and testicular function in boys affected by thalassemia.
21663467 - Soluble st2 is not independently associated with androgen and estrogen status in health...
17469287 - Measurement of thyroid hormones (thyroxine, t4; triiodothyronine, t3) in captive nondom...
18555227 - Serum inhibin b during controlled ovarian hyperstimulation: an additional criterion for...
455717 - An evaluation of the use of electrophoresis and carbon furnace atomic absorption spectr...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-2-9
Journal Detail:
Title:  The journal of sexual medicine     Volume:  -     ISSN:  1743-6109     ISO Abbreviation:  -     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-2-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101230693     Medline TA:  J Sex Med     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2012 International Society for Sexual Medicine.
Urology Research Options, Aurora, CO, USA Abbott, Abbott Park, IL, USA MedImmune, LLC., Gaithersburg, MD, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The influence of proximal ulnar morphology on elbow range of motion.
Next Document:  Gamma-aminobutyric acid (GABA)-B receptor 1 in cerebellar cortex of essential tremor.